SiRNA-Mediated Knockdown of ABCB1 Enhances the Efficacy of Doxorubicin and Vinorelbine in Breast Cancer Cells.
Zahra AbbasfardAbbas Behzad BehbahaniBanafsheh RastegariSirous NaeimiParisa MohamadynejadFatemeh SafariPublished in: Current pharmaceutical biotechnology (2024)
these findings suggest that combining siRNA, doxorubicin, and vinorelbine holds promise as a therapeutic strategy to overcome ABCB1-mediated multidrug resistance in breast cancer. Further investigations and clinical trials are warranted to evaluate its clinical efficacy rigorously.